journal article·2022-11-18Open access

Supramolecular assembly of pentamidine and polymeric cyclodextrin bimetallic core–shell nanoarchitectures

Alexandru-Milentie Hada, Nina Burduja, Marco Abbate, Claudio Stagno, Guy Caljon, Louis Maes, Nicola Micale, Massimiliano Cordaro, Angela Scala, Antonino Mazzaglia, Anna Piperno

Abstract

Advanced nanoscale antimicrobials, originated from the combination of noble metal nanoparticles (NPs) with conventional antimicrobial drugs, are considered the next generation of antimicrobial agents. Therefore, there is an increasing demand for rapid, eco-friendly, and relatively inexpensive synthetic approaches for the preparation of nontoxic metallic nanostructures endowed with unique physicochemical properties. Recently, we have proposed a straightforward synthetic strategy that exploits the properties of polymeric β-cyclodextrin (PolyCD) to act as both the reducing and stabilizing agent to produce monodispersed and stable gold-based NPs either as monometallic (nanoG) structures or core–shell bimetallic (nanoGS) architectures with an external silver layer. Here, we describe the preparation of a supramolecular assembly between nanoGS and pentamidine, an antileishmanial drug endowed with a wide range of therapeutic properties (i.e., antimicrobial, anti-inflammatory, and anticancer). The physicochemical characterization of the supramolecular assembly (nanoGSP) in terms of size and colloidal stability was investigated by complementary spectroscopic techniques, such as UV–vis, ζ-potential, and dynamic light scattering (DLS). Furthermore, the role of PolyCD during the reduction/stabilization of metal NPs was investigated for the first time by NMR spectroscopy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticles: synthesis and applications · Nanocluster Synthesis and Applications · Gold and Silver Nanoparticles Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (30)

Show source-provided references
1. 10.1021/acs.accounts.2c0009310.1021/acs.accounts.2c00093 ↗
2. 10.3390/molecules2703113410.3390/molecules27031134 ↗
3. 10.1016/j.cis.2021.10257810.1016/j.cis.2021.102578 ↗
4. 10.1039/d0tc03443f10.1039/d0tc03443f ↗
5. 10.1016/j.talanta.2020.12196010.1016/j.talanta.2020.121960 ↗
6. 10.1002/smll.20190279110.1002/smll.201902791 ↗
7. 10.2741/e82710.2741/e827 ↗
8. 10.2217/nnm-2017-023310.2217/nnm-2017-0233 ↗
9. 10.3762/bjnano.10.10410.3762/bjnano.10.104 ↗
10. 10.1016/j.msec.2020.11092410.1016/j.msec.2020.110924 ↗
11. 10.1515/ntrev-2022-005910.1515/ntrev-2022-0059 ↗
12. 10.1038/s41598-019-40816-y10.1038/s41598-019-40816-y ↗
13. 10.1002/adfm.20190926010.1002/adfm.201909260 ↗
14. 10.1016/j.carbpol.2022.11973610.1016/j.carbpol.2022.119736 ↗
15. 10.1016/j.ijantimicag.2010.05.00610.1016/j.ijantimicag.2010.05.006 ↗
16. 10.1007/s13346-022-01127-410.1007/s13346-022-01127-4 ↗
17. 10.3389/fchem.2021.62228610.3389/fchem.2021.622286 ↗
18. 10.1039/c5ra18019h10.1039/c5ra18019h ↗
19. 10.1016/j.ijpharm.2021.12076110.1016/j.ijpharm.2021.120761 ↗
20. 10.1002/jbm.b.3405810.1002/jbm.b.34058 ↗
21. 10.1021/acsomega.0c0203210.1021/acsomega.0c02032 ↗
22. 10.1016/j.biopha.2021.11129410.1016/j.biopha.2021.111294 ↗
23. 10.2147/ijn.s18596510.2147/ijn.s185965 ↗
24. 10.1016/j.carbpol.2014.09.03010.1016/j.carbpol.2014.09.030 ↗
25. 10.1002/aoc.607910.1002/aoc.6079 ↗
26. 10.1016/j.ijpharm.2012.09.03910.1016/j.ijpharm.2012.09.039 ↗
27. 10.1007/s10847-019-00885-y10.1007/s10847-019-00885-y ↗
28. 10.2217/nnm-2017-023310.2217/nnm-2017-0233 ↗
29. 10.1002/chem.20200357410.1002/chem.202003574 ↗
30. 10.1021/acs.jmedchem.5b0145610.1021/acs.jmedchem.5b01456 ↗